QX200™ AutoDG™ Droplet Digital™ PCR System (1864100)

The use of RNA as a therapeutic to effect clinically meaningful targets is an exciting new area of work with huge potential.

In this infographic, Bio-Rad provides an overview of how RNA can be used in a therapeutic application, some of the challenges associated with this new field, and how Droplet Digital™ PCR (ddPCR™) technology is helping address some of these challenges to fuel the RNA therapeutics revolution.

In this application note, Bio-Rad discusses migrating assays from real-time quantitative PCR (qPCR) to Droplet Digital PCR (ddPCR). These two PCR methods determine the concentration of sample DNA using fundamentally different approaches and a bridging study between the two methods presents data demonstrating the differences and similarities to consider.

This application note describes strategies for amplitude-based and probe-mixing multiplexing using the large portfolio of Droplet Digital PCR (ddPCR) Assays available through Bio-Rad.

This application note demonstrates the incorporation of Bio-Rad’s Droplet Digital™ PCR (ddPCR) system into the library preparation workflow, accurately quantifying and balancing libraries for Ion Torrent sequencing platforms. ddPCR provides highly precise measurements to quantify Ion Torrent libraries without the need for standards.

This comprehensive applications guide presents a variety of uses for the Droplet Digital™ PCR (ddPCR™) from Bio-Rad. Droplet Digital polymerase chain reaction was developed to provide high-precision, absolute quantification of nucleic acid target sequences with wide-ranging applications for both research and clinical diagnostic applications.

This poster presents an exploratory analysis into whether dynamic changes in the levels of plasma EGFR mutations post-osimertinib treatment are associated with clinical outcome. It presents data from the AURA Phase I study in patients with disease progression following prior therapy with an EGFR-TKI and T790M-positive baseline genotyping (in tumor tissue or plasma). It was found that early clearance of plasma EGFR mutations in patients receiving osimertinib therapy appears to be a prognostic marker for improved median progression-free survival of patients.

Detection and quantitation of specific mutations in circulating plasma holds promise for earlier and less invasive diagnosis of disease. Learn how a simple droplet digital PCR strategy can detect somatic mutations with high selectivity and sensitivity.

Monday, October 27, at 15:00 GMT | 16:00 CET | 11:00 EDT | 8:00 PDT

This webinar will explore the insights from the ddPCR World on Tour event in London and introduce the next evolution of Droplet Digital™ PCR (ddPCR™) technology. You’ll hear directly from fellow researchers and pioneers in the field as they share how ddPCR has advanced their studies, from detecting rare mutations to improving transplant monitoring. Plus, discover how Bio-Rad’s latest systems deliver exceptional sensitivity, simplicity, and performance, enabling absolute quantification, scalable workflows, and reliable results with minimal sample input.

Key learning objectives:

• Explore the latest ddPCR innovations and how they improve sensitivity, reproducibility, and ease of use.
• Hear about practical applications of ddPCR, from rare mutation detection to transplant monitoring.
• Gain real-world insights through user testimonials on how ddPCR has advanced their research.

The session will conclude with a Q&A, giving you the chance to ask our experts questions directly and gain practical insights to apply to your own research. Don’t miss this opportunity to see how ddPCR can transform your experiments.

Certificate of attendance

If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

Personalized treatments for cancer are multiplying. As they multiply, so do clinical questions, such as: Which targeted therapies will be most effective? Have the first signs of a relapse begun? When does a tumor become resistant to the current protocol? In this video, discover how Droplet Digital PCR technology, which can be utilized for the absolute quantification of nucleic acids, is being utilized for clinical applications.

Learn how liquid biopsies are replacing solid biopsies and are increasing the speed of cancer diagnosis, improving outcomes for patients. Also, find out how liquid biopsy can be used to quantify and monitor mutation, enabling rapid decision-making and treatment plans.

Emil Christensen from Aarhus University, Denmark, discusses the use of droplet digital PCR (ddPCR) in monitoring the progression of bladder cancer in patients. The detection of genetic alterations in patients’ DNA enables scientists to track the progression of the cancer.

Carolyn Reifsnyder, Senior Marketing Manager, Bio-Rad Laboratories, Inc., introduces new assays for genome edit detection using the droplet digital PCR system as well as the new ddSEQ™ Single-Cell Isolator, at AACR 2017. She discusses how Bio-Rad’s droplet digital PCR has become a mainstay in the field of liquid biopsy and mutation detection due to the level of sensitivity and precision it can achieve.

In this interview filmed at AACR 2017, hear how researchers at the Dana-Farber Cancer Institute are using Droplet Digital PCR to detect key mutations in cell-free DNA from liquid biopsies, helping improve understanding of drug resistance development as well as inform treatment decisions.

Professor of Genetics, Diptasri Mandal and graduate student, Kirsten Wood, of the Department of Genetics at Louisiana State University Health Sciences Center, explain how custom digital PCR assays are facilitating their research into hereditary biomarkers of prostate cancer.

Scientists at the New York University School of Medicine explain how digital PCR has enabled the identification of novel biomarkers of cancer from liquid biopsies. Digital PCR assists them in detecting and counting low amounts of cell-free DNA being investigated as a promising new biomarker for metastatic disease. Watch the video to learn more.

ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing

High capture efficiency and sensitivity of scATAC-Seq assay demonstrated in Nature Biotechnology study

Don’t miss April’s highlights thanks to our regular monthly round-up of all the most popular stories and resources in the clinical science community

Dr. Bruce Conklin, UCSF, discusses the potential of genome engineering as a therapy for genetic diseases

Booth #2439